References
1. Benham G., Charak R. Stress and sleep remain significant predictors of health after controlling for negative affect. Stress Health. 2019; 35 (1): 59–68. DOI: https://doi.org/10.1002/smi.2840
2. Cohen S., Gianaros A.P.J., Manuck S.B. Stage model of stress and disease. Perspect. Psychol. Sci. 2016; 11 (4): 56–63. DOI: https://doi.org/10.1177/1745691616646305
3. Zaytseva N.S., Sizyakina L.P. The role of innate immunity factors in the formation of adaptive reactions under stress. Immunologiya. 2021; 42 (3): 270–6. DOI: https://doi.org/10.33029/0206-4952-2021-42-3-270-276 (in Russian)
4. O’Connor D.B., Thayer J.F., Vedhara K. Stress and health: a review of psychobiological processes. Annu. Rev. Psychol. 2021; 72: 663–88. DOI: https://doi.org/10.1146/annurev-psych-062520-122331
5. Kuznik B.I., Davydov S.O., Landa I.V. Nerve growth factor (NGF) and its role in the conditions of norm and pathology. Uspekhi fiziologicheskikh nauk. 2019; 50 (4): 64–80. (in Russian)
6. Santucci D., Racca A., Alleva E. When nerve growth factor met behavior. Adv. Exp. Med. Biol. 2021; 1331: 205–14. DOI: https://doi.org/10.1007/978-3-030-74046-7_13
7. Kryzhanovskaya S.Yu., Zapara M.A., Glazachev O.S. Neurotrophins and adaptation to environmental stimuli: possibilities of expanding the «therapeutic potential» (a brief overview). Vestnik mezhdunarodnoy akademii nauk (Russkaya sektsiya). 2020; 1: 36–43. (in Russian)
8. Levchuk L.A., Vyalova N.M., Mikhalitskaya E.V., et al. The role of BDNF in the pathogenesis of neurological and mental disorders. Sovremennye problemy nauki i obrazovaniya. 2018; 6: 58. URL: https://science-education.ru/ru/article/view?id=28267 (in Russian)
9. Islands I.V., Golubeva N.V., Kuzovlev A.N., et al. Prognostic significance and therapeutic potential of brain neurotrophic factor BDNF in brain damage (review). Obshchaya reanimatologiya. 2019; 15 (1): 70–86. DOI: https://doi.org/10.15360/1813-9779-2019-1-70-86 (in Russian)
10. Duman R.S., Deyama S., Fogaça M.V. Role of BDNF in the pathophysiology and treatment of depression: activity-dependent effects distinguish rapid-acting antidepressants. Eur. J. Neurosci. 2021; 53 (1): 126–39. DOI: https://doi.org/10.1111/ejn.14630.
11. Carr R., Frings S. Neuropeptides in sensory signal processing. Cell Tissue Res. 2019; 375 (1): 217–25. DOI: https://doi.org/10.1007/s00441-018-2946-3
12. Kanunnikova N.P. Neuroprotective properties of neuropeptides. J. Grodno State Med. Univ. 2017; 15 (5): 492–8. DOI: https://doi.org/10.25298/2221-8785-2017-15-5-492-498
13. Samotrueva M.A., Yasenyavskaya A.L., Murtalieva V.K., et al. Experimental Substantiation of application of semax as a modulator of immune reaction on the model of «social» stress. Bull. Exp. Biol. Med. 2019; 166 (6): 754–8. DOI: https://doi.org/10.1007/s10517-019-04434-y
14. Vyunova T.V., Andreeva L.A., Shevchenko K.V., et al. An integrated approach to study the molecular aspects of regulatory peptides biological mechanism. J. Labelled Comp. Radiopharm. 2019; 62 (12): 812–22. DOI: https://doi.org/10.1002/jlcr.3785
15. Avgustinovich D.F., Kovalenko I.L., Kudryavtseva N.N. A model of anxious depression: persistence of behavioral pathology. Neurosci. Behav. Physiol. 2005; 35 (9): 917–24. DOI: https://doi.org/10.1007/s11055-005-0146-6
16. Koolhaas J.M., De Boer S.F., Buwalda B., et al. Social stress models in rodents: Towards enhanced validity. Neurobiol. Stress. 2017; 6: 104–12. DOI: https://doi.org/10.1016/j.ynstr.2016.09.003
17. Yasenyavskaya A.L., Samotrueva M.A., Myasoedov N.F., et al. The effect of semax on the level of interleukin-1ß in conditions of «social» stress. Meditsinskiy akademicheskiy zhurnal. 2019; 9 (S): 192–4. DOI: https://doi.org/10.17816/MAJ191S1192-194 (in Russian)
18. Fricker L.D. Carboxypeptidase E and the identification of novel neuropeptides as potential therapeutic targets. Adv. Pharmacol. 2018; 82: 85–102. DOI: https://doi.org/10.1016/bs.apha.2017.09.001
19. Thiele T.E. Neuropeptides and addiction: an introduction. Int. Rev. Neurobiol. 2017; 136: 1–3. DOI: https://doi.org/10.1016/bs.irn.2017.07.001